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Type I interferons (IFNs) (IFN-a, IFN-b) and type III IFNs (IFN-l) share many properties, including induction by
viral infection, activation of shared signaling pathways, and transcriptional programs. However, recent dis-
coveries have revealed context-specific functional differences. Here, we provide a comprehensive review
of type I and type III IFN activities, highlighting shared and distinct features from molecular mechanisms
through physiological responses. Beyond discussing canonical antiviral functions, we consider the adaptive
immune priming, anti-tumor, and autoimmune functions of IFNs. We discuss a model wherein type III IFNs
serve as a front-line defense that controls infection at epithelial barriers while minimizing damaging inflam-
matory responses, reserving the more potent type I IFN response for when local responses are insufficient.
In this context, we discuss current therapeutic applications targeting these cytokine pathways and highlight
gaps in understanding of the biology of type I and type III IFNs in health and disease.Introduction
Interferons (IFNs) are divided into three families (type I, type II,
and type III) on the basis of sequence homology, which corre-
sponds to the evolutionary relatedness, receptor usage, and
functional activity of these cytokines. The type II IFN family in-
cludes a single member, IFN-g, which has pro-inflammatory
and immunomodulatory functions that are distinct from the
type I and III IFNs; IFN-g has been reviewed elsewhere (Alspach
et al., 2018) and is not discussed herein. Type I IFNs originally
were identified on the basis of their antiviral activity (Isaacs and
Lindenmann, 1957; Isaacs et al., 1957), but subsequently were
recognized to have anti-proliferative and immunomodulatory
activities, as well as roles in modulating infection by non-viral
pathogens. It was nearly 50 years later that type III IFNs were
discovered (Kotenko et al., 2003; Sheppard et al., 2003), and
initially it was unclear why the host would maintain seemingly
redundant antiviral defense pathways. Although type I and type
III IFNs are genetically distinct and use different receptors, they
are induced by similar pathogen-sensing pathways and activate
related antiviral, anti-proliferative, and immunomodulatory gene
expression programs. The potential for type III IFNs to provide
supplementary antiviral protection at epithelial surfaces was
recognized early on, but it is now appreciated that type III IFNs
might provide a front-line defense that confers less collateral
damage than the more potent type I IFN response. This model
of type III IFN action stems from an improved understanding of
the cells and tissues in which type III IFNs exert their activity.
For example, type III IFNs function broadly at anatomic barrier
sites and have unique effects on hematopoietic cells, most strik-
ingly neutrophils. We also now have a greater understanding of
the regulatory mechanisms that distinguish type I and type III
IFN signaling. Furthermore, the discovery of translation-inde-
pendent effects of IFN signaling, as well as activation of non-ca-nonical signaling pathways, suggests the potential for previously
unappreciated mechanisms of IFN activity. Beyond spatial
segregation of IFN signaling, we now have an improved under-
standing of the mechanisms by which IFN-stimulated genes
(ISGs) exert their antiviral activities. Although excellent recent re-
views are available about distinct aspects of the antiviral
response induced by type I and type III IFN signaling (Crouse
et al., 2015; Garcı́a-Sastre, 2017; Hoffmann et al., 2015; Ingle
et al., 2018; Kotenko and Durbin, 2017; Lazear et al., 2015b;
Schoggins, 2018; Schreiber, 2017; Snell et al., 2017; Sorgeloos
et al., 2013; Wack et al., 2015; Wells and Coyne, 2018), our
goal is to provide a comprehensive overview of shared and
unique activities of type I and type III IFNs. In addition to their ca-
nonical antiviral activities, we further consider other functions of
IFNs, including adaptive immune priming, anti-tumor responses,
and effects on autoimmunity. We focus on human and mouse
IFNs, which are the best understood, but the diversity of IFNs
found among vertebrates suggests that comparative immu-
nology studies might reveal novel effector and regulatory mech-
anisms (Krause and Pestka, 2015). Since their discovery, IFNs
have been harnessed for therapeutic applications with some
clinical successes. Other promising applications might be re-
vealed by gaining a more complete understanding of IFN struc-
ture, signaling activity, function, and regulation.
Type I and Type III IFNs
IFNs are part of the class II cytokine family, which also includes
interleukin-10 (IL-10)-related cytokines (IL-10, IL-19, IL-20,
IL-22, IL-24, and IL-26). Despite limited primary sequence
homology, class II cytokines share a conserved structure
comprised of six a-helices. Their receptors have two extracel-
lular type III fibronectin domains that form the cytokine binding
site (Renauld, 2003) (Figure 1). Type I IFNs originally were
Figure 1. Canonical Type I and Type III IFN
Signaling
Type I and type III IFNs bind to distinct receptors but
activate similar signaling pathways and transcrip-
tional responses. The type I and type III IFN re-
ceptors are heterodimers comprised of IFNAR1 and
IFNAR2 subunits or IFNLR1 and IL10Rb subunits,
respectively. IFNs first bind one receptor chain with
high affinity (IFNAR2 or IFNLR1), then recruit a low-
affinity receptorchain (IFNAR1or IL10Rb) tocreatea
signaling-competent ternary complex. Receptor
dimerization activates TYK2 and JAK1 kinases,
which phosphorylate STAT1 and STAT2. Phos-
phorylated STAT1 and STAT2 heterodimers com-
plex with IRF9 to produce the transcription factor
ISGF3. ISGF3 binds to ISREs and promotes
expression of hundreds of ISGs. Type I and type III
IFNs also activate additional signaling pathways not
depicted in this figure.discovered as secreted factors that rendered cells refractory to 
viral infections (Isaacs and Lindenmann, 1957; Isaacs et al., 
1957). The molecular mechanisms underlying their antiviral ac-
tivities became better defined when the genes for these cyto-
kines were cloned in the 1980s and their cell surface receptors 
identified in the 1990s (reviewed in Vilcek, 2006). IFN gene fam-
ilies have evolved through gene duplication and divergence such 
that the complement of IFN genes varies among vertebrate spe-
cies (Krause and Pestka, 2015). In humans and mice, the type I 
IFN family includes multiple IFN-a subtypes (13 in humans, 14 
in mice) and single IFN-b, IFN-ε, IFN-k, IFN-u (humans), and 
IFN-z (mice) subtypes (Figure 2). All type I IFNs signal through 
a shared heterodimeric receptor, IFNAR, comprised of IFNAR1 
and IFNAR2 subunits. Type I IFNs bind IFNAR2 with high affinity, 
then recruit the low-affinity IFNAR1, creating a signaling-compe-
tent ternary complex. Type I IFN genes lack introns (except for 
IFN-k, which has one) and are clustered on human chromosome 
9 and mouse chromosome 4. Although there is considerable 
redundancy among type I IFNs, differences in promoter se-
quences and biochemical properties contribute to distinct func-
tional activities (Schreiber, 2017). Type III IFNs were discovered 
by two groups (Kotenko et al., 2003; Sheppard et al., 2003), and 
in humans include four subtypes, IFN-l1 (IL-29), IFN-l2 (IL-28A),IFN-l3 (IL-28B), and IFN-l4. IFN-l4 was
the last to be discovered, and is a pseu-
dogene in many human populations (Pro-
kunina-Olsson et al., 2013). In mice, the
type III IFN family consists of IFN-l2 and
IFN-l3; IFN-l1 is a pseudogene and the
genomic region encoding IFN-l4 is ab-
sent (Kotenko and Durbin, 2017; Wack
et al., 2015).
All type III IFNs signal through a
shared heterodimeric receptor, IFNLR,
comprised of IFNLR1 (also termed
IL28Ra) and IL10Rb. IFN-l binds IFNLR1
with high affinity, and then recruits the
low-affinity IL10Rb (which is shared with
other IL-10 family cytokines) to create a
signaling-competent ternary complex.
Type III IFN genes are clustered on hu-man chromosome 19 and mouse chromosome 7 and share a
5-exon gene structure with other IL-10 family cytokines,
although IFNL2 and IFNL3 have an additional 6th exon (Fox
et al. 2009; Sabat, 2010). In humans, multiple polymorphisms
in the IFNL locus are associatedwith clinical outcomes from hep-
atitis C virus (HCV) infection (Griffiths et al., 2015). Among these,
a frameshift mutation in the promoter of IFNL4 results in the loss
of IFN-l4 production in many non-African populations and
concomitant improved clearance of HCV (Prokunina-Olsson
et al., 2013). The pseudogenization of IFN-l4, along with selec-
tion for lower-potency variants, suggest IFN-l4 signaling has
been deleterious during human evolution (Bamford et al., 2018;
Key et al., 2014).
IFN signaling forms the foundation of the vertebrate innate im-
mune response to viral infections. ISG repertoire varies among
species, but a core set of90 ISGs induced in diverse mammals
suggests substantial conservation of the IFN-mediated antiviral
response throughout mammalian evolution (Shaw et al., 2017).
The significance of this system is evidenced by the variety of
mechanisms by which viruses evade or antagonize IFN induc-
tion, signaling, or effector functions (Garcı́a-Sastre, 2017; Hoff-
mann et al., 2015), as well as the susceptibility phenotypes
observed in humans and mice with genetic disruptions in IFN
Figure 2. Comparison of Type I and Type
III IFNs
Although their signaling pathways and transcrip-
tional responses have many similarities, some
features distinguish type I and type III IFNs: (1)
most type I IFN genes lack introns, whereas type III
IFN genes have 5 or 6 exons; (2) the type I IFN
family is larger, comprising 17 members in humans
and 18 in mice, compared with 4 type III IFN
members in humans and 2 in mice; (3) type I and
type III IFNs bind distinct receptors. The type I
IFN receptor (IFNAR) is ubiquitously expressed,
whereas the type III IFN receptor (IFNLR) is ex-
pressed preferentially on epithelial cells, as well as
neutrophils; (4) although the genes activated by
type I and type III IFN signaling are similar, differ-
ences in cell type specificity and signaling kinetics
result in distinct responses. The type I IFN
response is more potent, rapid, and transient,
whereas the type III IFN response is less potent,
slower, and sustained. Many cell types respond to
type I IFNs, resulting in a systemic response that is
more inflammatory. In contrast, the type III IFN
response is less inflammatory and concentrated at
epithelial and barrier surfaces.production or signaling (M€uller et al., 1994; Sancho-Shimizu
et al., 2011). The role of IFN signaling during bacterial infections
is more nuanced, given than IFN signaling protects against some
bacterial infections and exacerbates disease caused by others
(Boxx and Cheng, 2016).
IFN Signaling Pathways and the Antiviral Response
Despite their different receptors, the downstream signaling
pathways and transcriptional responses activated by type I
and III IFNs exhibit substantial overlap (Figure 3) (Kotenko
and Durbin, 2017; Wack et al., 2015). Both type I and type III
IFNs signal through the JAK-STAT pathway to activate the het-
erotrimeric transcription factor complex ISGF3, comprised of
phosphorylated STAT1 and STAT2, and interferon regulatory
factor 9 (IRF9). Activated ISGF3 translocates to the nucleus
and binds to IFN-stimulated response elements (ISREs) in the
upstream promoter regions of ISGs, which encode proteins
that act via a variety of mechanisms to restrict viral infection
(reviewed in Schneider et al., 2014; Schoggins, 2014, 2018).
Because ISGs generally are induced as part of a concerted
transcriptional program, the effects of individual ISGs can be
difficult to ascertain in isolation. However, recent work hasidentified molecular mechanisms behind
the antiviral effects of prominent ISGs
including viperin (Gizzi et al., 2018), inter-
feron-induced protein with tetratricopep-
tide repeats 1 (IFIT1) (Daffis et al., 2010;
Hyde et al., 2014; Pichlmair et al.,
2011), Mx1 (Haller et al., 2015), PKR
(Pfaller et al., 2011), OAS/RNASEL (Hor-
nung et al., 2014), and IFI6 (Richardson
et al., 2018). Because the signaling
cascade is overlapping, many functional
activities are shared between the two
IFN families. However, distinct biological
outcomes can result from differences inthe magnitude and kinetics of signaling and in the types of cells
that respond to type I versus type III IFNs.
Recent structural studies of IFN-l3 in complex with its hetero-
dimeric receptor highlight differences in the ternary complexes
of type I and III IFNs (Mendoza et al., 2017). The IFN-l ternary
complex has a distinct geometry compared with the type I IFN
(IFN-u) ternary complex (Thomas et al., 2011). In the IFN-u com-
plex, the two receptor chains bind on opposing faces of the cyto-
kine, which contrasts with the binding interface of the IFN-l3
ternary complex. Additionally, a large surface area of IFN-l3 re-
mains exposed in the ternary complex, whereas little surface
area of IFN-u is exposed in the ternary complex with IFNAR1
and IFNAR2 (Thomas et al., 2011). Lastly, the IFNLR1 and
IL10Rb chains make extensive stem-stem contacts that stabilize
the complex; similar contacts between IFNAR1 and IFNAR2 in
the type I IFN ternary complex were absent. In canonical type I
IFN signaling, cytokines bind with high affinity to IFNAR2 and
then form a ternary complex with IFNAR1 that mediates
signaling. However, unlike IFN-a, IFN-b can form a high-affinity
complex with IFNAR1, contributing to its potency and allowing
for IFNAR2-independent IFN-b signaling and a distinct ISG
profile (de Weerd et al., 2017; de Weerd et al., 2013). One
Figure 3. Induction and Antiviral Signaling
of Type I and Type III IFNs
(A andB) Type I IFNs (A) and type III IFNs (B) are both
induced when viral infection is detected by PRRs
including RIG-I like receptors (RLRs), Toll-like re-
ceptors (TLRs), and cGAS (not depicted). Differ-
ences in the subcellular localization of the PRR
response can favor production of type III over type I
IFNs (e.g., plasma membrane TLR4 signaling or
peroxisomal MAVS signaling). PRR signaling acti-
vates IRF-family transcription factors which,
together with NFkB, promote IFN expression. IFNs
are secreted by infected cells and signal in a para-
crine manner to uninfected cells to stimulate the
production of ISGs, which act by a variety of
mechanisms to induce an antiviral state. Among the
ISGs induced by IFN signaling are other IFNs, re-
sulting inapositive feedback loopofantiviral activity.determinant in the differential antiviral responses of type I and 
type III IFNs is the non-overlapping distribution of their respec-
tive receptors: IFNAR1 and IFNAR2 are expressed on virtually 
all nucleated cells, whereas IFNLR1 is expressed preferentially 
on epithelial cells. Accordingly, the antiviral effects of type III 
IFNs are especially evident at epithelial barriers, such as the 
gastrointestinal, respiratory, and reproductive tracts (Kotenko 
and Durbin, 2017; Lazear et al., 2015b; Wells and Coyne, 2018). 
The signaling pathways induced by type I and III IFNs have 
subtle differences that contribute to their distinct functions. 
Although both signaling pathways use JAK1 and TYK2 kinases 
to trigger the formation of the ISGF3 complex, in certain cell 
types, type III IFNs also activate JAK2 signaling (Lee et al., 
2012; Odendall et al., 2014). Furthermore, in addition to STAT1 
and STAT2, type I IFNs can also signal through STAT3. In 
some cases, STAT3 negatively regulated type I IFN signaling 
by inhibiting STAT1-dependent gene activation (Ho and Ivashkiv, 
2006; Wang et al., 2011), whereas in others, STAT3 contributedto type-I-IFN-mediated antiviral re-
sponses against influenza A virus (IAV)
and vaccinia virus by inducing a subset
of antiviral ISGs (Mahony et al., 2017).
STAT3 also has been implicated inmodu-
lating type-III-IFN-mediated expression
of microRNAs that mediate HCV repli-
cation or lung inflammatory responses
(Aboulnasr et al., 2015; Cohen and
Prince, 2013). In addition to the dominant
JAK-STAT signaling response, both type I
and type III IFNs can activate mitogen-
activated protein kinase (MAPK) signaling
(Platanias, 2005; Zhou et al., 2007). How-
ever, studies in intestinal organoid cul-
tures found that the antiviral response
induced by IFN-l, but not IFN-b, was
blocked by MAPK inhibitors, suggesting
differential effects of STAT-independent
signaling pathways (Pervolaraki et al.,
2017). Other STAT-independent IFN ac-
tivities include induction of neutrophil
degranulation and tightening of cell-cell
junctions in blood-brain barrier (BBB)endothelial cells, both of which occur in a translation-indepen-
dent manner (Broggi et al., 2017; Lazear et al., 2015a).
Transcriptome profiling studies have established that the type
I and type III signatures are overlapping. In general, type III IFNs
are less potent than type I IFNs, and the ISGs induced by type III
IFNs are a subset of those induced by type I IFNs (Crotta et al.,
2013; Doyle et al., 2006; Marcello et al., 2006; Zhou et al.,
2007). Increasing the amount of IFN-l augments the number of
ISGs to match that seen with type I IFNs, suggesting that the
ISG repertoire reflects the magnitude of the signaling response.
Indeed, antiviral ISGs such as MX1, viperin, and the IFITM, IFIT,
and OAS family members, are induced by both type I IFN and
type III IFNs, although the type I IFN response is more potent,
especially at lower doses and earlier time points (Zhou et al.,
2007). However, in more relevant primary cells and tissues, dis-
tinctions have emerged. For example, in human vaginal epithelial
cells, a subset of ISGs (e.g., CXCL10, CXCL11, IFIT3, IFI30 and
TDRD7) were uniquely or more highly induced by IFN-l1 than by
IFN-b (Caine et al., 2019). Because the study was carried out at 
one time point and with a single IFN dose, it is not known whether 
these differential ISG expression patterns would be sustained at 
earlier time points or with different IFN doses. Although the over-
all repertoire of genes induced by type I and III IFNs is shared, the 
kinetics of induction are distinct. ISG induction by type I IFNs 
peaks early and declines, whereas more sustained expression 
occurs with type III IFNs (Bolen et al., 2014; Jilg et al., 2014; Kohli 
et al., 2012; Marcello et al., 2006; Voigt and Yin, 2015). These ef-
fects might be linked to the rapid downregulation of type I IFN 
signaling by negative regulatory ISGs such as ISG15, USP18, 
and Tyro3, Axl, and Mer (TAM) receptors (Franç ois-Newton 
et al., 2011; Rothlin et al., 2007; Zhang et al., 2015). Mathemat-
ical modeling and experimental data suggest that the difference 
in kinetics between type I and type III IFNs is not due to receptor 
expression levels, but rather due to intrinsic qualities of the two 
signaling pathways (Pervolaraki et al., 2018).
Both type I and type III IFNs are induced after detection of 
pathogen-associated molecular patterns (PAMPs) and engage-
ment and activation of cytosolic (e.g., RIG-I, MDA5, and cGAS) 
or endosomal (e.g., TLR3 and TLR4) pattern-recognition recep-
tors (PRRs). For some PRRs, differences in the location of 
PAMP engagement can affect the type of IFN produced. TLR4 
signaling in endosomes results in type I IFN production (Kagan 
et al., 2008), whereas TLR4 engagement at the plasma mem-
brane induces type III IFNs. (Odendall et al., 2017). These distinct 
patterns of IFN induction might contribute to the protective activ-
ity of type III IFNs at epithelial barriers that continually encounter 
commensal microbiota and their PAMPs.
PRR signaling induces IFN expression by activating IRF tran-
scription factors. In the classical model of type I IFN induction, 
PRR activation leads to IRF3 activation, followed by IFN-b 
induc-tion (Honda et al., 2006; Paun and Pitha, 2007). IFN-b 
stimulates a first wave of ISG transcription, including the IFN-
inducible tran-scription factor IRF7. Subsequent IRF7 activation 
then induces expression of multiple IFN-a subtypes, which 
mediate a second wave of ISG transcription. This model does 
not function in all cell types, however, and both IRF5 and IRF7 
can participate in the first wave of type I IFN induction (Honda et 
al., 2005; Lazear et al., 2013). Analogous to type I IFNs, the type 
III IFNs also are induced by IRF3 and/or IRF7 (Osterlund et al., 
2007). Addition-ally, at least one type III IFN, IFN-l1, can be 
induced by IRF1 (Odendall et al., 2014), whereas IRF1 is not 
considered a primary driver of type I IFN expression (Reis et al., 
1994). Other PRR signaling pathways, such as the cytosolic 
DNA sensor Ku70, also can uniquely induce type III IFNs 
compared with type I IFNs (Zhang et al., 2011). The in vivo 
biological relevance of these distinct IRF-mediated induction 
patterns still remains unclear, but might be linked to differences 
in temporal and spatial re-sponses to viral infection (Pulverer et 
al., 2010).
Tissue-Specific Effects of IFN Signaling
Given the similar transcriptional responses induced by type I and 
type III IFNs, what is the purpose of maintaining seemingly 
redundant antiviral defense systems? Type III IFN signaling ap-
pears to serve as a first-line defense that is lower in magnitude, 
less inflammatory, and concentrated at anatomic barriers (re-
viewed in Kotenko and Durbin, 2017; Lazear et al., 2015b; 
Wack et al., 2015; Wells and Coyne, 2018). In this paradigm,only when the initial type III IFN-mediated defense is breached
is it necessary to activate the more potent, but more inflamma-
tory, systemic type I IFN response. This sequence allows im-
mune signaling to be spatially segregated, and the effects of
type III IFNs are most evident at epithelial barriers such as the
gastrointestinal, respiratory, and female reproductive tracts, as
well as tissue barriers such as the BBB and placenta. The con-
stant exposure of external epithelial surfaces to commensal
and pathogenic microbes necessitates a balance between pro-
tective and pathological immune responses. Type III IFN respon-
siveness at epithelial surfaces is related to the relatively high
expression of IFNLR1 on epithelial cells. It also correlates with
the density of peroxisomes in epithelial tissues, as these organ-
elles favor type III IFN over type I IFN production downstream of
MAVS signaling (Odendall et al., 2014). Consistent with a key role
for type III IFN signaling at barrier surfaces, a human primary im-
munodeficiency patient with a homozygous loss-of-function
allele of IFNAR2 controlled naturally encountered pathogens suf-
ficiently well to survive to more than one year of age. However,
the patient succumbed to measles-mumps-rubella vaccination
in which subcutaneous administration of live viruses bypassed
epithelial barriers protected by type III IFNs (Duncan et al., 2015).
All epithelial surfaces encounter environmental microbes, but
nowhere is the amount and complexity of exposure as great as
in the gastrointestinal tract. Here, IFN responses must provide
protection from microbial infection without initiating destructive
inflammatory responses (reviewed in Ingle et al., 2018). The mi-
crobiome provides protection against viral infections and other
intestinal insults, and its protective effects are mediated by IFN
signaling (Baldridge et al., 2015; Kernbauer et al., 2014; Martin
et al., 2018; Steed et al., 2017). Antiviral responses in the gut
are dominated by type III rather than type I IFN signaling. This
is a direct consequence of high IFNLR and low IFNAR expression
on intestinal epithelial cells, which are targets for enteric viruses
including norovirus, reovirus, rotavirus, and enteroviruses (Bal-
dridge et al., 2017; Good et al., 2019; Johansson et al., 2007;
Lin et al., 2016; Mahlakõiv et al., 2015; Nice et al., 2015; Pott
et al., 2011). In contrast, lamina propria cells generally express
greater levels of IFNAR than IFNLR, and type I IFN signaling re-
stricts systemic spread of enteric viruses if they invade beyond
the epithelium. In addition to their antiviral activity, type III IFNs
serve important immunomodulatory functions in the gastrointes-
tinal tract. For example, enteric-virus-induced type III IFNs
activate an anti-inflammatory program in neutrophils, resulting
in a STAT1- and translation-independent suppression of degran-
ulation and reduction in reactive oxygen species (Broggi
et al., 2017).
In contrast to the IFN-l-specific responsiveness of intestinal
epithelial cells, respiratory tract epithelial cells respond to both
type I and type III IFNs (Hamming et al., 2013). Accordingly,
both Ifnar1/ and Ifnlr1/ mice are more susceptible to infec-
tion with respiratory viruses, and treatment of mice or respiratory
epithelial cells with type I or type III IFNs restricts viral replication
(reviewed in Lazear et al., 2015b;Wells andCoyne, 2018). Never-
theless, recent studies have revealed location, cell type, and
kinetic differences in how type I and type III IFNs control respira-
tory infections. After infection with IAV or other respiratory tract
pathogens, epithelial cells rapidly produce type III IFNs, and
type I IFNs were produced later and/or to a lesser extent (Crotta
et al., 2013; Espinosa et al., 2017; Fox et al., 2015; Galani et al., 
2017; Jewell et al., 2010; Okabayashi et al., 2011). Type III IFNs 
are important for controlling viral infection in the upper respira-
tory tract, whereas there is more functional redundancy between 
type I and III IFNs in the lower respiratory tract (Klinkhammer 
et al., 2018). Bone marrow chimera and conditional knockout ex-
periments reveal that IFN signaling in epithelial cells is key to 
controlling IAV infection (Crotta et al., 2013; Galani et al., 
2017). In contrast, control of Aspergillus fumigatus was mediated 
by IFN signaling in hematopoietic cells (Espinosa et al., 2017). 
These differing requirements for IFN signaling in the respiratory 
tract might reflect the target cells of different pathogens. For 
example, IAV infection is largely restricted to epithelial cells, 
whereas fungal spores are internalized by phagocytes. In 
contrast to its antiviral effects, IFN signaling can augment 
some bacterial infections (Boxx and Cheng, 2016), which can 
contribute to disease during viral-bacterial co-infection. For 
example, IAV-induced IFN promotes Streptococcus pneumonia 
colonization in the upper respiratory tract (Nakamura et al., 
2011), and IFN induced by respiratory syncytial virus enhances 
Pseudomonas aeruginosa biofilm formation (Hendricks et al., 
2016). IFN signaling shapes the inflammatory response to respi-
ratory viruses, and has protective and pathological outcomes. 
For example, type I IFN signaling controls respiratory syncytial 
virus replication in the lungs, but also promotes inflammation-
induced disease (Goritzka et al., 2014; Goritzka et al., 2015). 
Although neutrophils express ISGs in response to both type I 
and type III IFNs, inflammatory cytokines (e.g., Tnf, Il1b, Il6, 
and Ccl2) were induced predominantly by IFN-a and not IFN-l. 
Accordingly, Ifnlr1/ mice infected with IAV exhibited greater in-
flammatory burdens in the lungs than did wild-type (WT) or 
Ifnar1/ mice (Galani et al., 2017). These observations support 
a model in which type III IFNs serve as the first-line response for 
controlling viral infection in respiratory tract epithelial cells while 
minimizing immune pathology.
The need to control infection while limiting inflammation is 
especially important in the central nervous system (CNS), which 
relies heavily on innate antiviral responses because leukocyte 
trafficking across the BBB is tightly regulated (reviewed in Klein 
and Hunter, 2017). Neurons, astrocytes, and microglia all pro-
duce and respond to type I IFNs (Delhaye et al., 2006; Drokhlyan-
sky et al., 2017; Hwang and Bergmann, 2018), whereas type III 
IFNs do not appear to contribute substantially to the antiviral 
response within the CNS parenchyma (Lazear et al., 2015a; 
Sommereyns et al., 2008; Sorgeloos et al., 2013). In addition to 
inhibiting viral replication, IFNs independently control viral infec-
tion in the CNS by restricting BBB permeability and neuroinva-
sion. Both type I and type III IFNs induce cell junction tightening 
in brain microvasculature endothelial cells, and this response is 
independent of STAT1 signaling and new protein synthesis (Dan-
iels et al., 2014; Lazear et al., 2015a). The BBB tightening effects 
of IFN signaling protect mice from viral neuroinvasion (Daniels 
et al., 2014; Douam et al., 2017; Lazear et al., 2015a). In addition 
to effects on endothelial cells, type I IFN signaling on astrocytes 
also modulates BBB permeability in a brain-region-specific 
manner (Daniels et al., 2017).
The barrier tightening effects of IFNs are not unique to the 
CNS, because they also tighten epithelial barriers in the respira-
tory and gastrointestinal tracts (LeMessurier et al., 2013; Oden-dall et al., 2017). Compromised epithelial barrier integrity contrib-
utes to disease progression in the autoimmune skin conditions
psoriasis and atopic dermatitis. Of note, atopic dermatitis is
associated with bacterial (e.g., Staphylococcus aureus) and viral
(e.g., herpes simplex virus [HSV], human papilloma virus [HPV],
and molluscum contagiosum poxvirus) infections of the skin,
whereas psoriasis is not. Skin lesions from psoriasis patients
exhibit high basal expression of ISGs and type III IFNs, but not
type I IFNs, which might contribute to protection from cutaneous
infections (Wolk et al., 2013). Conversely, type I IFNs contribute
to inflammatory cascades that exacerbate psoriasis (reviewed in
Grine et al., 2015), though the cytokine responses involved are
complex, and it is unclear to what extent type III IFNs contribute
to this process. Type I IFN responses in the skin might be
affected by IFN-k, which is produced specifically and constitu-
tively by keratinocytes (LaFleur et al., 2001) but has a lower affin-
ity for IFNAR2 than other type I IFNs (Harris et al., 2018). HPV
epigenetically represses IFN-k expression (Reiser et al., 2011;
Rincon-Orozco et al., 2009), suggesting that IFN-k might have
a protective role in keratinocytes in the skin and female repro-
ductive tract, although its antiviral properties have not been
investigated extensively.
In primary human cervical and vaginal epithelial cells cultured
ex vivo, both type I and type III IFNs induce ISG expression
(Caine et al., 2019). Ifnar1/ and Ifnlr1/ mice both exhibit
increased susceptibility to vaginal infection with HSV-2 or Zika
virus (ZIKV), consistent with these cytokines eliciting protective
antiviral responses in the female reproductive tract (Ank et al.,
2008; Caine et al., 2019; Svensson et al., 2007; Yockey et al.,
2016). Whereas IFN-a and IFN-b contribute to antiviral immunity
in the female reproductive tract by mechanisms similar to those
in other tissues, an additional type I IFN, IFN-ε, might have spe-
cific roles in the female reproductive tract. Unlike other IFNs,
IFN-ε is regulated by hormonal status and is not induced by
PRR signaling (Fung et al., 2013; Hermant et al., 2013). IFN-ε
has a lower affinity for IFNAR2 and signals with lower potency
than other type I IFNs, which might prevent excessive immune
activation (Harris et al., 2018; Stifter et al., 2018). Nonetheless,
IFN-ε induces ISG expression, restricts viral replication in cell
culture, and protects mice from vaginal infection with HSV-2 or
Chlamydia muridarum (Fung et al., 2013; Stifter et al., 2018;
Tasker et al., 2016). The diminished potency of IFN-ε (as well
as IFN-k) compared with other type I IFNs highlights the potential
for the induction of different functional outcomes even among
IFNs signaling through the same receptor. In contrast to the pro-
tective effects of IFN-ε, IFN-b exacerbates Chlamydia disease
in the genital tract by eliciting inflammatory immunopathology
(Nagarajan et al., 2008).
The maternal-fetal interface is an anatomic barrier with com-
plex immune regulation due to the need to protect the fetus
from maternal pathogens while avoiding immune rejection of
semi-allogeneic fetal tissue (reviewed in Ander et al., 2019;
Yockey and Iwasaki, 2018). The interface between the maternal
blood supply and fetal-derived placenta is formed by syncytio-
trophoblasts, which are refractory to infection due in part to
their constitutive secretion of cytokines including type III IFNs
(Bayer et al., 2016; Corry et al., 2017). As maternally derived
decidual cells respond to type I and type III IFNs, placenta-
derived IFNs could induce an antiviral state on both sides of
the maternal-fetal interface (Corry et al., 2017). Accordingly, re-
combinant IFN-l2 administered to pregnant Ifnar1/ mice 
induced ISGs in both placental and decidual cells (Bierne et al., 
2012). In pregnant mice, Listeria monocytogenes infection 
induced Ifnl2 and Ifnl3 expression in placental and decidual tis-
sue, but the effect of IFN signaling on fetal infection was not as-
sessed (Bierne et al., 2012). Type III IFNs restrict transplacental 
transmission of ZIKV in mice but not viral burden in other tissues, 
suggesting a specific role at the maternal-fetal interface (Jagger 
et al., 2017). In contrast, type I IFNs have a dominant role in con-
trolling ZIKV infection in most tissues in mice (Lazear et al., 
2016). This results in part from species restrictions, including the 
inability of ZIKV to antagonize murine STAT2 and STING 
proteins (Ding et al., 2018; Gorman et al., 2018; Grant et al., 
2016; Kumar et al., 2016). Accordingly, Ifnar1/ mice exhibit 
enhanced ZIKV transplacental transmission and fetal pathology 
due to uncon-trolled maternal viral replication (Jagger et al., 
2017; Miner et al., 2016; Yockey et al., 2016). In addition to a 
protective anti-viral response, type I IFN signaling might 
contribute to placental damage, fetal pathology, and fetal 
demise. Placental macro-phages are susceptible to ZIKV and 
produce IFN-a (but not IFN-b or IFN-l) in response to infection, 
providing a source of type I IFN within the infected placenta 
(Quicke et al., 2016). In hu-man midgestation chorionic villus 
explants, IFN-b stimulation induced pathological morphological 
changes (syncytial knots and sprouts) (Yockey et al., 2018). 
Women with dysregulated type I IFN signaling (sustained IFN 
production or impaired recep-tor downregulation) exhibit poor 
pregnancy outcomes including pre-eclampsia as well as 
neurodevelopmental defects similar to those induced by 
congenital infection, altogether consistent with a role for 
dysregulated type I IFN responses in placental damage 
(Andrade et al., 2015; Crow and Manel, 2015; Meuwissen et al., 
2016; Sanchis et al., 2005). In contrast, IFN-l3 treatment did not 
elicit pathologic changes in human villus explants (Yockey et al., 
2018), consistent with a protective antiviral role for type III IFN 
signaling in the placenta. The need to balance protective and 
pathological effects of type I IFN signaling during fetal develop-
ment might continue into infancy. For example, the choroid 
plexus, which lines the brain ventricles, does not respond effi-
ciently to type I IFN in neonates, leaving them vulnerable to 
HSV encephalitis. In contrast, this tissue efficiently mounts an 
IFN-dependent antiviral response in adults (Wilcox et al., 2016).
Immunomodulatory Effects of IFNs
Beyond their direct antiviral actions, type I IFNs regulate adap-
tive immune responses. Type I IFN signaling can promote or 
inhibit T cell priming depending on the temporal relationship be-
tween IFNAR signaling and T cell receptor (TCR) engagement 
(Crouse et al., 2015). IFNAR signaling after or coinciding with 
TCR stimulation promotes T cell proliferation, survival, and 
effector differentiation. However, IFN signaling before or without 
TCR stimulation elicits a negative regulatory effect, suppressing 
proliferation, and inducing apoptosis. These opposing effects of 
type I IFN signaling are thought to occur through recruitment of 
different STAT transcription factors (van Boxel-Dezaire et al., 
2006); STAT1 is pro-inflammatory, anti-proliferative, and pro-
apoptotic, whereas STAT3, STAT4, and STAT5 induce T cell 
survival and differentiation. Type I IFNs also can modulate 
T cell responses indirectly by (1) stimulating class I and II majorhistocompatibility complex (MHC) expression, (2) inducing
expression of co-stimulatory molecules (e.g., CD80 and CD86)
on antigen-presenting cells, (3) stimulating migration of anti-
gen-presenting cells via increased C-C chemokine receptor
type 5 (CCR5), CCR7, and lymphocyte function-associated anti-
gen 1 (LFA-1) expression, (4) inducing negative regulators of nat-
ural killer (NK) cell activation and cytotoxicity (e.g., NKp46 and
class I MHC), and (5) inducing dendritic cells (DCs) to produce
chemokines (e.g., CXCL9 and CXCL10) and cytokines (e.g.,
IL-15) that enhance cross-presentation and promote T cell pro-
liferation and survival (Crouse et al., 2015; Le Bon et al., 2003).
Although type I IFNs activate T cell responses during acute infec-
tion, chronic IFN exposure can be detrimental to T cells that
control pathogens. For example, during lymphocytic choriome-
ningitis virus (LCMV) infection, persistent type I IFN exposure
caused DCs to produce the inhibitory cytokine IL-10 and cell
surface protein PD-L1. Blockade of type I IFN signaling during
the chronic phase resulted in enhanced IFN-g responses,
decreased expression of negative regulatory molecules,
improved T cell immunity, and control of LCMV infection (Teijaro
et al., 2013; Wilson et al., 2013). Remarkably, IFN-a and IFN-b
have disparate effects: IFN-b blockade improves lymphoid
structure, promotes lymphocyte migration, and mitigates T cell
exhaustion, altogether promoting virus clearance. Conversely,
blockade of IFN-a affected early viral dissemination but did not
alter T cell exhaustion (Ng et al., 2015).
Type III IFNs also modulate T cell responses, but this effect is
most likely indirect, perhaps via DCs, because T cells express
minimal or no IFNLR1 (Zanoni et al., 2017). The addition of
IFN-l during peripheral blood mononuclear cell (PBMC) stimula-
tion or a mixed lymphocyte reaction reduced the production of T
helper 2 (Th2) cytokines (IL-4, IL-5, and IL-13) and increased pro-
duction of IFN-g (Dai et al., 2009; Jordan et al., 2007; Srinivas
et al., 2008). Furthermore, increased IFN-l production by
PBMCs promoted Th1 skewing in response to a viral vaccine
(Egli et al., 2014), and Ifnlr1/ mice exhibited Th2 skewing and
worse disease in an asthma model (Koltsida et al., 2011).
Together, these findings indicate a Th1-skewing activity for
type III IFNs. IFN-l1 treatment also impaired differentiation of
central memory into effector memory T cells. Administration of
IFN-l as an adjuvant for immunization of HIV gag DNA plasmid
vaccine reduced the numbers and activity of regulatory T cells
and increased the magnitude and quality of CD8+ T cell re-
sponses (Morrow et al., 2009). In mice, studies with acute
LCMV infection suggested an inhibitory role of type III IFNs on
T cells because Ifnlr1/ mice had increased expansion of
CD4+ and CD8+ T cells and enhanced memory T cell responses.
However, IFN-l signaling had a distinct effect during persistent
LCMV infection including markedly diminished T cell responses
observed in Ifnlr1/ mice (Misumi and Whitmire, 2014). Dispa-
rate results also were observed in flavivirus models: there were
no differences in the magnitude or quality of antigen-specific
CD8+ T cell responses between WT and Ifnlr1/mice infected
with West Nile virus, whereas loss of type III IFN signaling re-
sulted in impaired T cell activation in the context of yellow fever
virus infection (Douam et al., 2017; Lazear et al., 2015a). Thus,
specific virus-host and immune cell interactions might determine
the effect of type III IFN signaling on T cell proliferation andmatu-
ration.
The effect of type I IFN signaling on B cell and antibody re-
sponses varies depending on the context and the antigen. 
Type I IFN induces DCs to produce B cell stimulatory cytokines 
(e.g., B cell activating factor [BAFF] and a proliferation-inducing 
ligand [APRIL]), which enhance immunoglobulin (Ig) class 
switching (Le Bon et al., 2001; Litinskiy et al., 2002). Selective 
ablation of IFNAR1 in B cells impaired IFN-a-mediated stimula-
tion of antibody responses and subclass switching, suggesting 
a direct effect of type I IFNs on B cells (Le Bon et al., 2006). How-
ever, in other contexts, type I IFNs can inhibit IL-7-dependent 
growth and survival of B cell precursors in vitro and ex vivo. 
Moreover, IFN-a treatment diminished bone marrow and splenic 
cellularity and markedly reduced numbers of B lineage cells (Lin 
et al., 1998). Consistent with a negative regulatory effect, during 
chronic LCMV infection, anti-IFNAR1 antibody treatment pro-
moted survival and differentiation of LCMV-specific B cells and 
accelerated the generation of neutralizing antibodies (Fallet 
et al., 2016; Moseman et al., 2016; Sammicheli et al., 2016).
B cell and antibody responses most likely are regulated by type 
III IFN signaling, although the effects have not been consistent 
across models. IFN-l1 augmented TLR-mediated activation of hu-
man B cells and IgG production (de Groen et al., 2015), and an IFN-
l3 adjuvant used with an HIV gag DNA plasmid vaccine enhanced 
HIV-specific IgG2a responses (Morrow et al., 2009). In contrast, re-
combinant IFN-l3 inhibited IAV-stimulated Th2 cytokine release, 
B cell proliferation, and production of antiviral IgG (Egli et al., 
2014). In West Nile virus and LCMV infection models, no differ-
ences in humoral responses were observed between WT and 
Ifnlr1/ mice (Lazear et al., 2015a; Misumi and Whitmire, 2014).
Anti-tumor Effects of IFNs
Type I IFNs can act on tumors directly by blocking cell cycle pro-
gression and inducing apoptosis. They also have indirect anti-tu-
mor activities, via priming immune cells to promote clearance and 
prevent metastasis (Booy et al., 2015; Borden, 2019; Di Trolio 
et al., 2015). In the context of chemotherapy and/or radiation ther-
apy, type I IFN production by tumor and immune cells stimulates 
an adaptive (largely T cell) immune response against tumor-cell-
associated antigens. This adjuvant effect of type I IFNs is needed 
because many cancers induce an exhausted and dysfunctional 
immune state inadequate for tumor clearance (Snell et al., 2017). 
Given their pro-apoptotic and immunomodulatory actions, type I 
IFNs were anticipated to be effective therapies against multiple 
malignancies (reviewed in Borden, 2019). Indeed, treatment with 
IFN-a (by itself or as part of combination therapy) has moderate 
success and clinical response for breast cancer, melanoma, and 
renal carcinoma (Budhwani et al., 2018). For melanoma in partic-
ular, IFN-a therapy has produced improvements in relapse-free 
and overall survival in large randomized trials (Kirkwood et al., 
2001; Kirkwood et al., 1996). However, systemic type I IFN treat-
ment has been limited as an anti-tumor modality by lack of efficacy 
for some tumors, propensity for adverse side effects, and poor 
tolerability of regimes for patients.
Type III IFNs also exert direct effects against cancer cells by 
inhibiting cell proliferation and promoting apoptosis (reviewed 
in Lasfar et al., 2016). However, because fewer cell types 
express IFNLR1 and respond to IFN-l, it could serve as a 
more targeted anti-cancer therapy with diminished side effects 
compared to IFN-a. In mice, melanoma cells engineered to ex-press IFN-l2 exhibited greater rejection or slower growth (Lasfar
et al., 2006). Type III IFNs inhibited growth of several different
tumor cell lines and diminished local and metastatic tumor for-
mation in mice including cancers from lung, liver, breast, and
prostate (Abushahba et al., 2010; Lasfar et al., 2016; Li et al.,
2008; Numasaki et al., 2007; Sato et al., 2006; Tezuka et al.,
2012). Consistent with these findings, Ifnlr1/ mice are more
susceptible to sarcoma formation induced by chemical carcino-
gens as well as death in transplanted tumor models (Souza-Fon-
seca-Guimaraes et al., 2015). Type III IFNs can also act indirectly
on tumors. IFN-l suppressed tumor angiogenesis in a mouse
model of melanoma by modulating the tumor microenvironment
(Lasfar et al., 2006). IFN-l also augments T cell and NK cell re-
sponses to multiple tumors including melanoma, lung adenocar-
cinoma, and breast cancer (Lasfar et al., 2016). A direct effect of
IFN-l signaling in NK cells was suggested after the failure of
Ifnlr1/ NK cells to suppress tumor growth in vivo (Souza-Fon-
seca-Guimaraes et al., 2015). Finally, IFN-l signaling on mam-
mary epithelial cells induced expression of the chemokine
CXCL10, which recruits CD4+ T cells into the tumor microenvi-
ronment (Burkart et al., 2013). Because IFN-l can alter tumori-
genesis both directly and indirectly, it could have utility as an
adjunctive anti-cancer therapy. Beyond these mechanisms, in-
duction of IFNs in response to viral infections also can promote
anti-tumor responses. Infection with an oncolytic vesicular sto-
matitis virus triggered IFN-l expression in hematopoietic cells
in vitro and sensitized melanoma to anti-tumor NK cell recogni-
tion and activation in vivo (Wongthida et al., 2010).
IFN Signaling and Autoimmunity
Unchecked responses to pathogens or PAMPs are associated
with sustained innate immune signaling and autoimmune dis-
ease. Interferonopathies are caused by monogenic allele vari-
ants that result in chronic IFN signaling and severe inflammatory
disease, such as Aicardi-Goutières syndrome or stimulator
of interferon genes (STING)-associated vasculitis with onset in
infancy syndrome, as well as other autoimmune diseases
including systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), and inflammatory vasculopathy. Mutations in
several genes act by distinct mechanisms to cause sustained
type I IFN signaling and resultant disease: (1) loss-of-function
mutations leading to increased cytosolic DNA (TREX1 and
SAMHD1) or RNA/DNA hybrid sensing (RNASEH2); (2) loss-of-
function mutations leading to defects in RNA editing and aber-
rant recognition of self-RNA in the cytosol (ADAR1); (3) gain-of-
function mutations in cytosolic RNA or DNA sensors leading to
constitutive activation (MDA5 and STING); (4) loss-of-function
mutations leading to altered unfolded protein responses and
enhancedMAVS signaling (SKIV2L); and (5) loss-of-function mu-
tations in negative regulators of IFNAR signaling (USP18) (Crow
and Manel, 2015; Rodero and Crow, 2016; Yan, 2017).
The first evidence for a linkage between type I IFN signaling
and autoimmunity came from patients receiving IFN therapy for
chronic viral infections. A subset of these individuals developed
signs of autoimmune diseases including SLE, RA, and polymyo-
sitis (Okanoue et al., 1996). Consistent with this observation, high
amounts of serum IFN-a were present in SLE patients with dis-
ease activity, and genes in the IFN pathway (e.g., MDA5, TLR7,
IRF5, and IRF7) are featured in clinical progression studies of
SLE in humans (Thorlacius et al., 2018). Neutrophils and forma-
tion of extracellular traps (NETs) are observed in the kidneys of 
SLE patients, and type I IFN signaling can prime neutrophils to 
form NETs after stimulation with the complement factor C5a 
(Martinelli et al., 2004). The type I IFN response is also activated 
in patients with Sjö gren’s syndrome, a chronic autoimmune dis-
ease that features focal lymphocytic infiltration of the exocrine 
glands, often causing dry eyes and dry mouth (Thorlacius et al., 
2018).
The chronic skin disease psoriasis is characterized by epithe-
lial cell hyperproliferation, impaired barrier function, and inflam-
mation. Skin lesions from psoriasis patients exhibit high IFN-l1 
and ISG expression, which occurs in the absence of sustained 
expression of type I IFNs and appears to be driven by Th17 cells 
(Wolk et al., 2013). Analysis of IFN-l-treated human keratino-
cytes revealed induction of the chemokines CXCL10 and 
CXCL11, which attract NK cells, CD8+ T cells, and CD4+ T cells 
(Witte et al., 2016). Elevated IFN-l expression in psoriatic lesions 
was associated with upregulation of these chemokines 
compared with non-lesional skin from these patients or skin of 
healthy donors, both of which lack IFN-l production (Witte et al., 
2016).
The relationship between IFN-l and autoimmune arthritis de-
pends on the disease model. In the context of SLE, IFN-l mRNA 
and protein amounts are higher in patients with active arthritis 
than in healthy controls, and serum IFN-l amounts correlate with 
Th17 cytokine production and the extent of dis-ease (Oke et al., 
2017; Wu et al., 2011). RA patients had higher IFN-l1 mRNA 
levels in PBMCs than healthy matched controls (Wu et al., 2013). 
However, in mice, treatment with IFN-l reversed the 
development of collagen-induced arthritis by reducing numbers 
of pro-inflammatory Th17 and gd T cells in the joints and inguinal 
lymph nodes (Blazek et al., 2015). This study showed that IFN-l 
exerts an anti-inflammatory activity by restricting recruitment of 
IL-1b-expressing neutrophils; this result contrasts with the anti-
inflammatory effects of IFN-l in the intestine, where type III IFN 
signaling in neutrophils pre-vented granule release (Broggi et al., 
2017).
Clinical Applications of Type I and Type III IFNs
The antiviral and immunomodulatory properties of type I IFNs 
have generated interest in their clinical use to control viral infec-
tions, enhance antigen presentation, and promote anti-tumor re-
sponses (Table 1). Although pre-clinical experiments suggest 
that type III IFNs might provide therapeutic benefits with dimin-
ished side effects compared with type I IFNs, no IFN-l drug is 
approved for use in humans.
Since their initial discovery, there has been interest in harness-
ing the antiviral properties of IFNs for therapeutic use, and the 
greatest success to date was achieved with HCV. Prior to the 
advent of direct-acting antiviral therapy (which targets the HCV 
protease polymerase, and NS5A protein), IFN-a alone or in com-
bination with ribavirin was the mainstay of anti-HCV therapy (Da-
vis et al., 1989; Di Bisceglie et al., 1989; Heim, 2013). The mech-
anism of activity of IFN-a against HCV has remained somewhat 
uncertain, although it most likely is a combination of direct anti-
viral mechanisms and immunomodulatory effects on CD8+ T cell 
responses. Although iterative improvement in IFN-a treatment 
efficacy was achieved with pegylation and in combination withribavirin, ultimately challenges including viral escape mecha-
nisms, refractory IFN-a signaling in the liver, modest sustained
virological response rates, and drug toxicity have relegated
IFN-a treatment to a second-tier status in most developed coun-
tries (Sarasin-Filipowicz et al., 2008). The failure of IFN therapy
against HCV is highest in patients with a pre-existing elevated
ISG signature. The reduced responsiveness to IFN in some pa-
tients is thought to be due to altered IFN signaling pathways,
epigenetic modification, and diminished transcription and/or
translation responsiveness (Snell et al., 2017). Notwithstanding
these limitations, pegylated IFN-a in combination with ribavirin
remains a treatment option especially for patients with favorable
IFNL genotypes (Huang et al., 2017). Although no IFN-l drug is
approved for use in humans, dose-ranging studies evaluated
the safety, efficacy, and pharmacokinetics of pegylated IFN-l
therapy in chronic HCV infection (NCT00565539). A phase IIb
study showed similar efficacy of pegylated IFN-l1 treatment as
for IFN-a treatment for chronic HCV infection (Muir et al., 2014;
Muir et al., 2010). IFN-l1 treatment was associated with
improved or similar rates of virological response with fewer
side effects than IFN-a in chronic HCV infection.
IFN-a treatment of chronic hepatitis B virus (HBV) infection
was first reported in 1976, when four treated patients showed
marked reductions or clearance in viral antigens (Greenberg
et al., 1976). A 24-week treatment course of pegylated-IFN-
a2A administered once weekly resulted in a higher response
rate (24% versus 12%) than standard IFN-a, as defined by loss
in HBV antigenemia, reductions in HBV DNA in blood, and
improvement in serum liver enzymes (Cooksley et al., 2003).
Based on its convenience, patient compliance, and likely effi-
cacy, pegylated-IFN-a2A has replaced standard IFN-a therapy.
Analogous to HCV treatment, the mechanism of action of IFN
therapy against HBV has remained uncertain, but it most likely
acts on multiple steps of the HBV life cycle as well as enhances
NK and CD8+ T-cell-mediated clearance of infected cells. IFN-a
in part inhibits HBV replication epigenetically by decreasing RNA
transcription of pregenomic RNA and subgenomic RNA from
covalently closed circular DNA (Belloni et al., 2012). As another
potential mechanism, IFN-a induces APOBEC3G protein
expression, which results in G to A hypermutation in HBV DNA
and inhibition of replication (Suspène et al., 2005). Nonetheless,
the standard 48-week pegylated-IFN-a2A therapy is difficult to
tolerate (Terrault et al., 2016), and treatment is contraindicated
in pregnant women and in those with advanced liver disease
and decompensated cirrhosis. Following a dose ranging trial
that confirmed its safety in humans (NCT01204762), a phase
IIb trial showed that pegylated IFN-l therapy also enhanced
NK and CD8+ T cell effector responses that reduced HBV viral
replication and antigenemia (Phillips et al., 2017). More recently,
phase II trials with pegylated IFN-lwere initiated against chronic
infection with hepatitis delta virus (HDV), which exacerbates HBV
disease (NCT02765802). In preliminary results, patients in one of
the pegylated IFN-l treatment groups experienced a 2.4 log10
mean decline in HDV-RNA, and 4 out of 10 patients were HDV-
RNA negative at the end of treatment.
Treatment of cancer-promoting infections such as HCV and
HBV is an indirect means bywhich IFN therapies combat cancer,
but the anti-tumor effects of IFNs have also been evaluated
more directly. Before the development of more targeted cancer
Table 1. Clinical Applications of Type I and III IFNs
Interferon Form Clinical Uses Status Reference
IFN-a-2a recombinant leukemia, melanoma,
kaposi’s sarcoma
approved (Roferon-A) (Cascinelli et al., 2001)
IFN-a-2a pegylated chronic HBV, chronic HCV,
HPV (condylomata acuminata)
approved (Pegasys) (McHutchison et al., 2009;
Reichard et al., 1998)
IFN-a-2b recombinant leukemia, melanoma, multiple
myeloma,
carcinoid tumor,
chronic HBV, chronic HCV,
Bechet’s disease
approved (Intron-A) (Janssen et al., 2005; Yao et al., 2017)
IFN-a-2b pegylated chronic HCV, melanoma approved (PegIntron) (Eggermont et al., 2008; Hansson
et al., 2011; Lau et al., 2005; Manns
et al., 2001; McHutchison et al., 2009)
IFN-b-1a recombinant multiple sclerosis approved (Avonex, Rebif) (Hauser et al., 2017; Kappos et al., 2015)
IFN-b-1a pegylated multiple sclerosis approved (Plegridy) (Khan et al., 2015; Newsome et al., 2016)
IFN-b-1b recombinant multiple sclerosis approved (Betaseron,
Actoferon)
(Bayas and Gold, 2003)
IFN-l-1a pegylated chronic HDV phase 2, completed 12/18 NCT02765802
IFN-l-1 pegylated chronic HCV phase 1, completed 10/09 NCT00565539
IFN-l-1 pegylated HBV phase 2, completed 12/13 NCT01204762 (Phillips et al., 2017)immunotherapies, type I IFNs alone or in combination with con-
ventional chemotherapy were used to treat selected hematolog-
ical malignancies (e.g., lymphoma, chronic myeloid leukemia, 
and hairy cell leukemia), and solid tumors (Kaposi’s sarcoma 
and renal cell carcinoma). Type I IFNs (IFN-a2A, IFN-a2B, and 
more recently, pegylated IFN-a2B) are still part of a therapeutic 
regimen against melanoma, principally as adjuvant therapy after 
surgical resection in high-risk patients. Type I IFNs are thought to 
exert their activity against melanoma by increasing the number 
of antigen-presenting cells infiltrating the tumor, decreasing 
the number of circulating regulatory T cells, altering the cytokine 
environment, changing the STAT1 and STAT3 signaling balance 
in tumor cells and host lymphocytes, and inducing self-recogni-
tion with auto-antibodies (Di Trolio et al., 2015). A meta-analysis 
of melanoma patients found that IFN-a improved disease-free 
outcome and survival, although the benefit was modest (Mocel-
lin et al., 2010). In the future, IFN-a treatment might be combined 
with other immunotherapies to control or eliminate tumors and 
metastatic disease. This approach is premised on the ability of 
IFN-a to condition autologous DCs for adoptive cell immunother-
apies and vaccines as well as the ability of type I IFNs to enhance 
NK and T cell activation, thereby augmenting drugs that 
promote immunogenic cell death or immune recognition of tu-
mor neoantigens.
Although dysregulated IFN signaling can mediate some auto-
immune conditions, type I IFNs have been used to treat multiple 
sclerosis (MS), a chronic, debilitating autoimmune disease char-
acterized by inflammation in the CNS. In MS patients, genetic 
and/or environmental triggers induce activation and CNS migra-
tion of autoreactive T and B cells that respond to antigens similar 
to myelin and cause injury to myelin sheaths and oligodendro-
cytes, thereby altering neuronal functions. After an initial report 
of successful intrathecal therapy in ten patients (Jacobs et al., 
1981), IFN-b became the first major drug class used for treat-
ment of MS with its approval in 1993 (The IFNB Multiple SclerosisStudy Group, 1993). IFN-b therapy reduced the relapse rate, the
development of brain lesions, and the progression of disability
(Dhib-Jalbut andMarks, 2010). In one 21-year follow-up analysis
of MS patients, IFN-b-1b therapy showed a 46.8% reduction in
the long-term all-cause mortality compared with that in placebo
(Goodin et al., 2012). Despite decades of clinical use, the mech-
anism of action of IFN-b in MS remains only partially understood
(Jakimovski et al., 2018), and is thought to be related to the
downregulation of the MHC class II expression on the antigen-
presenting cells, induction of the regulatory T cells and the inhib-
itory cytokine IL-10, inhibition of T cell proliferation, and reduced
adhesion molecule expression and inhibition of T cell migration
across the BBB (Dhib-Jalbut and Marks, 2010).
Concluding Remarks
Type I and type III IFNs were first recognized for their antiviral ac-
tivity, but it is now appreciated that they also have a multitude of
immunomodulatory functions that influence tumor responses,
autoimmune disease, and microbial infection. Although many
of the activities induced by type I and type III IFNs overlap, spatial
and kinetic differences in their responses allow type III IFNs to
provide front-line protection at barrier surfaces, thereby mini-
mizing the activation of the systemic type I IFN response and
consequent immune pathology. In addition to epithelial cells,
the range of cell types now known to respond to type III IFNs
has expanded, and neutrophils are an example of a highly IFN-
l-responsive cell type that can exert activities through non-ca-
nonical pathways. IFN-l-mediated neutrophil activation, as
well as cell junction tightening by type I and type III IFNs, stands
out for being STAT- and translation-independent. Along with
activation of MAPK signaling by type I and type III IFNs and
IFNAR2-independent signaling by IFN-b, this suggests that
IFNs might have previously unappreciated activities that occur
through distinct signaling pathways. Given that the dominant
JAK-STAT signaling pathway activated by type I and type III
IFNs is the same, it is unsurprising that they induce highly similar 
transcriptional responses. However, distinct transcriptional and
functional responses might become more evident as these 
studies are extended to more physiologically relevant experi-
mental systems, in which cell- or tissue-specific differences in
signaling or effector molecules could influence the outcome of 
IFN signaling. It remains to be seen whether any specific ISGs 
are uniquely induced by type I versus type III IFNs, or whether 
dif-ferences in the type I and type III function will be fully 
attributable
to differences in signaling potency and kinetics or tissue-specific 
responsiveness. Likewise, the specific functions of individual IFN 
subtypes that signal through the same receptor (e.g., 17 different
human type I IFNs) remains unclear. The presence of large multi-
gene IFN families is a conserved feature of vertebrates, even 
though particular IFN genes do not necessarily have orthologs
in all species. In this review, we have discussed only human 
and mouse IFNs, but the number and diversity of IFN genes pre-
sent in nature provides a wealth of opportunities to discover new 
IFN properties and biology.
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interferonopathies. Nat. Rev. Immunol. 15, 429–440.
Daffis, S., Szretter, K.J., Schriewer, J., Li, J., Youn, S., Errett, J., Lin, T.Y., 
Schneller, S., Zust, R., Dong, H., et al. (2010). 20-O methylation of the viral 
mRNA cap evades host restriction by IFIT family members. Nature 468, 
452–456.
Dai, J., Megjugorac, N.J., Gallagher, G.E., Yu, R.Y., and Gallagher, G. (2009). 
IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 re-
sponses in human naive and memory T cells. Blood 113, 5829–5838.
Daniels, B.P., Holman, D.W., Cruz-Orengo, L., Jujjavarapu, H., Durrant, D.M., 
and Klein, R.S. (2014). Viral pathogen-associated molecular patterns regulate 
blood-brain barrier integrity via competing innate cytokine signals. MBio 5, 
e01476–e14.
Daniels, B.P., Jujjavarapu, H., Durrant, D.M., Williams, J.L., Green, R.R., White, 
J.P., Lazear, H.M., Gale, M., Jr., Diamond, M.S., and Klein, R.S. (2017). 
Regional astrocyte IFN signaling restricts pathogenesis during neurotropic 
viral infection. J. Clin. Invest. 127, 843–856.
Davis, G.L., Balart, L.A., Schiff, E.R., Lindsay, K., Bodenheimer, H.C., Jr., Per-
rillo, R.P., Carey, W., Jacobson, I.M., Payne, J., and Dienstag, J.L.; Hepatitis 
Interventional Therapy Group (1989). Treatment of chronic hepatitis C with re-
combinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. 
J. Med. 321, 1501–1506.
de Groen, R.A., Groothuismink, Z.M., Liu, B.S., and Boonstra, A. (2015). IFN-l 
is able to augment TLR-mediated activation and subsequent function of pri-
mary human B cells. J. Leukoc. Biol. 98, 623–630.
de Weerd, N.A., Vivian, J.P., Nguyen, T.K., Mangan, N.E., Gould, J.A., Braniff, 
S.J., Zaker-Tabrizi, L., Fung, K.Y., Forster, S.C., Beddoe, T., et al. (2013). 
Structural basis of a unique interferon-b signaling axis mediated via the recep-
tor IFNAR1. Nat. Immunol. 14, 901–907.
de Weerd, N.A., Matthews, A.Y., Pattie, P.R., Bourke, N.M., Lim, S.S., Vivian, 
J.P., Rossjohn, J., and Hertzog, P.J. (2017). A hot spot on interferon a/b recep-
tor subunit 1 (IFNAR1) underpins its interaction with interferon-b and dictates 
signaling. J. Biol. Chem. 292, 7554–7565.
Delhaye, S., Paul, S., Blakqori, G., Minet, M., Weber, F., Staeheli, P., and Mich-
iels, T. (2006). Neurons produce type I interferon during viral encephalitis. Proc. 
Natl. Acad. Sci. USA 103, 7835–7840.
Dhib-Jalbut, S., and Marks, S. (2010). Interferon-beta mechanisms of action in 
multiple sclerosis. Neurology 74 (Suppl 1 ), S17–S24.
Di Bisceglie, A.M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., 
Waggoner, J., Goodman, Z., Banks, S.M., and Hoofnagle, J.H. (1989). Recom-
binant interferon alfa therapy for chronic hepatitis C. A randomized, double-
blind, placebo-controlled trial. N. Engl. J. Med. 321, 1506–1510.
Di Trolio, R., Simeone, E., Di Lorenzo, G., Buonerba, C., and Ascierto, P.A.
(2015). The use of interferon in melanoma patients: a systematic review. Cyto-
kine Growth Factor Rev. 26, 203–212.
Ding, Q., Gaska, J.M., Douam, F., Wei, L., Kim, D., Balev, M., Heller, B., and 
Ploss, A. (2018). Species-specific disruption of STING-dependent antiviral 
cellular defenses by the Zika virus NS2B3 protease. Proc. Natl. Acad. Sci. 
USA 115, E6310–E6318.
Douam, F., Soto Albrecht, Y.E., Hrebikova, G., Sadimin, E., Davidson, C., Ko-
tenko, S.V., and Ploss, A. (2017). Type III interferon-mediated signaling is crit-
ical for controlling live attenuated yellow fever virus infection in vivo. MBio 8, 
e00819-17.
Doyle, S.E., Schreckhise, H., Khuu-Duong, K., Henderson, K., Rosler, R., Sto-
rey, H., Yao, L., Liu, H., Barahmand-pour, F., Sivakumar, P., et al. (2006). Inter-
leukin-29 uses a type 1 interferon-like program to promote antiviral responses 
in human hepatocytes. Hepatology 44, 896–906.
Drokhlyansky, E., Gö z Ayt€urk, D., Soh, T.K., Chrenek, R., O’Loughlin, E., Ma-
dore, C., Butovsky, O., and Cepko, C.L. (2017). The brain parenchyma has a 
type I interferon response that can limit virus spread. Proc. Natl. Acad. Sci. 
USA 114, E95–E104.
Duncan, C.J., Mohamad, S.M., Young, D.F., Skelton, A.J., Leahy, T.R., Mun-
day, D.C., Butler, K.M., Morfopoulou, S., Brown, J.R., Hubank, M., et al.
(2015). Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci. Transl. 
Med. 7, 307ra154.Eggermont, A.M., Suciu, S., Santinami, M., Testori, A., Kruit, W.H., Marsden,
J., Punt, C.J., Salès, F., Gore, M., Mackie, R., et al.; EORTC Melanoma Group
(2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation
alone in resected stage III melanoma: final results of EORTC 18991, a rando-
mised phase III trial. Lancet 372, 117–126.
Egli, A., Santer, D.M., O’Shea, D., Barakat, K., Syedbasha,M., Vollmer, M., Ba-
luch, A., Bhat, R., Groenendyk, J., Joyce, M.A., et al. (2014). IL-28B is a key
regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog.
10, e1004556.
Espinosa, V., Dutta, O., McElrath, C., Du, P., Chang, Y.J., Cicciarelli, B., Pitler,
A., Whitehead, I., Obar, J.J., Durbin, J.E., et al. (2017). Type III interferon is a
critical regulator of innate antifungal immunity. Sci. Immunol. 2, eaan5357.
Fallet, B., Narr, K., Ertuna, Y.I., Remy, M., Sommerstein, R., Cornille, K.,
Kreutzfeldt, M., Page, N., Zimmer, G., Geier, F., et al. (2016). Interferon-driven
deletion of antiviral B cells at the onset of chronic infection. Sci. Immunol. 1,
eaah6817.
Fox, B.A., Sheppard, P.O., andO’Hara, P.J. (2009). The role of genomic data in
the discovery, annotation and evolutionary interpretation of the interferon-
lambda family. PLoS One 4, e4933.
Fox, J.M., Crabtree, J.M., Sage, L.K., Tompkins, S.M., and Tripp, R.A. (2015).
Interferon lambda upregulates IDO1 expression in respiratory epithelial cells
after influenza virus infection. J. Interferon Cytokine Res. 35, 554–562.
François-Newton, V., Magno de Freitas Almeida, G., Payelle-Brogard, B.,
Monneron, D., Pichard-Garcia, L., Piehler, J., Pellegrini, S., and Uzé, G.
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